Is Buying Cascadian Therapeutics Inc (USA) (CASC) Here a Winning Strategy?

September 17, 2017 - By Clifton Ray

The stock of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) is a huge mover today! The stock increased 4.09% or $0.15 on September 15, reaching $3.82. About 847,604 shares traded or 164.62% up from the average. Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 30.85% since September 17, 2016 and is downtrending. It has underperformed by 47.55% the S&P500.
The move comes after 9 months positive chart setup for the $193.11 million company. It was reported on Sep, 17 by We have $4.13 PT which if reached, will make NASDAQ:CASC worth $15.45 million more.

Analysts await Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to report earnings on November, 6. They expect $-0.28 earnings per share, up 48.15 % or $0.26 from last year’s $-0.54 per share. After $-0.30 actual earnings per share reported by Cascadian Therapeutics Inc (USA) for the previous quarter, Wall Street now forecasts -6.67 % EPS growth.

More notable recent Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) news were published by: which released: “BRIEF-Mark Lampert says resigning from Cascadian Therapeutics’ board” on January 17, 2017, also with their article: “Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President …” published on January 04, 2017, published: “Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on …” on August 01, 2017. More interesting news about Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) were released by: and their article: “Cascadian Therapeutics: Worth Much More Than The Present Share Price” published on March 23, 2017 as well as‘s news article titled: “Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in …” with publication date: July 11, 2017.

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The company has market cap of $193.11 million. The Firm focuses on the development of therapeutic products for the treatment of cancer. It currently has negative earnings. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor 2 inhibitor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.